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BUKTI SEROLOGI JANGKITAN DENGGI DALAM PRIMAT 
BUKAN MANUSIA DI SEMENANJUNG MALAYSIA 
 
ABSTRAK 
Jangkitan Virus Denggi (DENV) berlaku di kalangan manusia dan di dalam 
kitaran Silvatik.  Pada tahun 2008 seorang pelajar universiti didiagnoskan dengan 
Demam Hemorajik Denggi (DHF) selepas ia mengembara di Semenanjung Malaysia 
dan pemencilan darah selanjutnya menunjukkan bahawa jangkitan itu adalah Serotip-2 
DENV Silvatik.  Kawasan Malaysia dengan kepadatan populasi yang tinggi didapati 
tidak mempunyai sebarang maklumat semasa berkenaan dengan kitaran DENV Silvatik.  
Oleh kerana DENV Silvatik menyebabkan penyakit teruk pada manusia, maka 
mengkenalpastikan lokasi dan spesies perumah pada kitaran jangkitan DENV Silvatik 
merupakan langkah kritikal yang pertama dalam penilaian risiko yang diutarakan oleh 
ejen zoonosis ke atas populasi manusia yang hidup berdampingan dengan spesies 
perumah ini.  Tujuan utama kajian ini adalah untuk memperolehi antibodi peneutralan 
bagi DENV-2 dari beruk liar.  Sampel darah telah diekstrak dari 430 Macaca 
fascicularis, 6 M. nemestrina, dan 6 Semnopithecus cristatus yang berhidup di lima 
negeri di Semenanjung Malaysia dan diperiksa dengan ujian Plaque Reduction 
Neutralization Test (PRNT). Antibodi peneutralan bagi DENV-2 telah ditemui pada 67 
individu M. fascicularis dan 1 individu M. nemestrina yang disampel di Pahang, Negeri 
Sembilan, dan Selangor.  Antara sampel-sampel yang didapati mengandungi antibodi 
	   ix	  
peneutralan bagi DENV-2, dua berasal dari kawasan dengan populasi Demam 
Hemorajik Denggi seramai 1.8 juta pesakit yang mana pemencilan darah selanjutnya 
menunjukkan bahawa ianya merupakan Serotip-2 DENV. Sampel peneutralan DENV-2 
diperolehi dari 20 beruk dalam pensampelan tunggal di Negera Sembilan.  Kekurangan 
bukti serologi dan ketiadaan pemencilan virus mencadangkan bahawa kitaran DENV 
Silvatik atau DENV manusia ditumpah kembali (spillback) kepada populasi beruk yang 
hidup berdampingan dengan populasi manusia yang berkepadatan tinggi.  Kaedah 
kawalan denggi semasa tidak mengambilkira kesan-kesan limpahan zoonosis strain 
Silvatik ke atas populasi manusia atau kesan-kesan tumpahan kembali DENV manusia 
kepada spesies primate bukan-manusia walaupun kedua-dua kesan ini merupakan 
pertimbangan yang amat penting dalam kesihatan awam.  Oleh yang demikian lebih 
banyak kajian lanjutan diperlukan untuk menentukan ancaman yang dihadapai oleh 
populasi manusia yang hidup di zon kemunculan ini.      
 
 
 
 
 
 
 
 
 
	   x	  
SEROLOGICAL EVIDENCE OF DENGUE INFECTION IN NON-
HUMAN PRIMATES IN PENINSULAR MALAYSIA 
 
ABSTRACT 
Dengue viruses (DENV) circulate in both human and sylvatic cycles.  In 2008, a 
Malaysian university student was diagnosed with dengue hemorrhagic fever (DHF) and 
a sylvatic DENV serotype 2 was isolated from his blood.  Current information on 
sylvatic DENV cycles in these heavily populated areas of Malaysia is nonexistent.  
Sylvatic DENV can cause severe disease (DHF) in humans.  Therefore, the objective of 
this study was to determine the location and host species of sylvatic DENV cycles as a 
first step in assessing the risk that such zoonotic viruses pose to the surrounding human 
population.  In this study, 430 Macaca fascicularis, six Macaca nemestrina, and six 
Semnopithecus cristatus monkeys from five states in Peninsular Malaysia were trapped 
from the wild and screened for DENV-2 neutralizing antibodies using the Plaque 
Neutralization Reduction Test (PRNT). DENV-2 neutralizing antibodies were found in 
67 M. fascicularis (16%) and one M. nemestrina (17%) macaques from Pahang, Negeri 
Sembilan, and Selangor.  Two seropositive monkeys were sampled from areas with a 
population of 1.8 million people. DENV-2 neutralizing samples were obtained from 20 
macaques in a single outing in Negeri Sembilan.  The limitations of serological evidence 
and absence of virus isolation suggest that the DENV-2 neutralizing antibodies detected 
in this study are evidence for either the presence of sylvatic DENV cycles or of human 
DENV spillback into macaques living near human populations.  Current dengue control 
	   xi	  
measures do not account for the zoonotic spillover of sylvatic strains into the human 
population or the spillback of human DENV into non-human primates. The blood 
isolation of a DENV from a macaque is needed to establish the identity of the virus that 
currently circulates in primates living within these zones of emergence.
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CHAPTER 1 – INTRODUCTION 
 
 
1.1 Background 
Dengue viruses (DENV) are the etiologic agents of two acute febrile diseases 
known as dengue (D) and severe dengue (SD) - a more severe presentation of the disease 
that includes severe hemorrhaging and organ impairment. (WHO 2009) This mosquito-
borne viral disease is spreading rapidly with an enormous impact on public health: 2.5 
billion people are exposed to the risk of dengue infection and the impact and scope of 
dengue epidemics worldwide has been on a precipitous rise, aided by unchecked human 
population growth in endemic regions and ensuing reclamation and repurposing of land.  
(WHO 2014) Given its pantropical distribution and the great number of people afflicted 
yearly, dengue merits consideration as a public health emergency of international 
concern. 
Classified as arboviruses (athropod-borne viruses), dengue viruses belong to the 
genus Flavivirus and are known to occur in four antigenically distinct serotypes: DENV-
1, 2, 3, 4 (Calisher et al., 1989). Epidemics of dengue fever are primarily caused by 
strains of DENV that are restricted to humans as the principal reservoir and amplifying 
host.  The main vectors of such infections are the domestic and peridomestic Aedes 
aegypti or Aedes albopictus mosquitoes. There also exist, in West Africa and Southeast 
Asia, separate and ecologically discrete strains of sylvatic enzootic dengue virus that 
circulate in non-human primates, utilizing forest canopy-dwelling Aedes spp. 
mosquitoes as vectors (Robin et al., 1980). The epidemic (henceforth called endemic) 
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strains of DENV are thought to have emerged independently from sylvatic cycles 
(Holmes & Twiddy 2003) and viral spillover into human populations with severe disease 
has been documented in West Africa and, more recently, Peninsular Malaysia, South 
East Asia (Saluzzo et al., 1986; Cardosa et al., 2009; Vasilakis et al., 2011). Sylvatic 
DENV has demonstrated the ability to spillover into a human population resulting in 
severe illness here in Malaysia, where a sylvatic DENV was isolated from the blood of a 
critically ill university student (Cardosa et al., 2009) and West Africa (Franco et al., 
2011).   
The mounting evidence that endemic DENVs diverged from their sylvatic 
ancestors relatively recently underscores the need to regard this zoonotic disease as a 
significant risk to public health. Consequently, assessing the potential of sylvatic dengue 
reemergence deserves attention of the highest priority.  Globally, programs geared at 
reducing or eradicating dengue from human populations rely on vector control or the 
development of a future DENV vaccine. These efforts may prove less effective or even 
untenable should either one or both of two unknown scenarios prove true: 1) Endemic 
DENVs are able to be maintained by non-human primates where they can reemerge into 
a human population are the completion of a successful vector eradication/vaccination 
program or 2) Sylvatic DENVs spill over into and adapt to a human population through 
a bridge vector re-establishing an endemic transmission cycle after the completion of a 
vector eradication/vaccination program. The likelihood of both scenarios is currently 
still unknown.  
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1.2 Statement of the Problem 
Studies conducted by Albert Rudnick in Selangor, Malaysia during the 1970s 
resulted in multiple isolations of sylvatic dengue viruses both from Aedes spp. vectors 
and non-human primates (Rudnick 1986). Over the past 30 years, large-scale 
development and repurposing of land in a dengue endemic country (Malaysia) has 
resulted in the concentration of human population in the zone of emergence, placing 
humans in direct contact with epizootic/sylvatic DENV cycles.  A DENV virus isolated 
from a patient with severe dengue traveling in the same area yielded a DENV-2 that fell 
within the sylvatic clade and closely matched a sylvatic DENV-2 previously isolated by 
Rudnick (P8-1407/1970) (Cardosa et al., 2009). 
In spite of the rapid population movement and land development, there exists an 
information gap regarding the geographic location/distribution, prevalence, and strains 
of sylvatic DENV currently infecting forest/peri-domestic vectors and their primate 
hosts.  Other unknowns include the ability of endemic dengue viruses to infect a sylvatic 
vector or sylvatic host, thereby reentering a forest cycle and rendering it protected from 
standard dengue virus control and eradication measures. If endemic dengue viruses 
originated from sylvatic lineages, understanding the circumstances in which sylvatic 
dengue spills into human populations is a question of paramount importance to public 
health. 
Furthermore, there has been no research on these sylvatic DENV cycles in 
Malaysia in the past 30 years and much to uncover about how these enzootic cycles 
interact with endemic dengue and nearby human populations. To that end, ecological 
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studies which target specific areas most at risk for sylvatic dengue spillover into the 
human population should be conducted – for Southeast Asia, in the same general area of 
Selangor, Malaysia where the student who developed a sylvatic DENV infection 
traveled proximate to developing severe symptoms.  
The aim of this study was to conduct a serosurvey of nonhuman primates for 
antibodies to DENV as a first step in determining if an enzootic sylvatic DENV cycle 
still exists in Peninsular Malaysia. Serum samples were collected from monkeys caught 
in traps or by routine wildlife officer patrols from Perhilitan / Department of Wildlife, 
Peninsular Malaysia from as many individuals and different locations as possible and 
screened for antibodies that bind DENV. The information that these ecological surveys 
provide will constitute a critical fist step in ascertaining the potential of a sylvatic 
dengue reemergence event and its potential threat to public health by identifying 
possible locations of enzootic DENV transmission. 
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CHAPTER 2 – LITERATURE REVIEW 
 
 
2.1 Dengue Fever Clinical Classification 
In 1997, the WHO classified symptomatic dengue virus infections into groups of 
three categories: undifferentiated fever, dengue fever (DF) and dengue hemorrhagic 
fever (DHF). DHF was further separated by severity into grade I, grade II, grade III and 
grade IV. Grade III and grade IV were defined as dengue shock syndrome (DSS). A 
rigorous literature review of this classification revealed difficulties in applying the 
criteria for DHF in a clinical situation (Bandyopadhyay, Lum and Kroeger 2006) 
resulted in a new set of WHO case classification guidelines in 2009. 
 Under the new classification system, symptomatic DENV infections are grouped 
into two main groups: dengue (D) and severe dengue (SD). D is further divided into D 
and dengue with warning signs (D + WS) (eg. abdominal pain, persistent vomiting, 
mucosal bleeding etc.) in order to better help clinicians with triage of symptomatic 
patients. (WHO 2009) While the D/SD was intended to replace DF/DHF/DSS, both 
classification systems are still in use as of the printing of this manuscript. In order to 
avoid the confusion that may result from converting from one classification system to 
another both systems are used here in accordance with the original publication 
referenced. 
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2.2 History and Spread of Dengue 
 Descriptions of fever and illness clinically compatible with the symptoms of 
dengue fever have been reported as early as 992 A.D. during the Northern Sung Dynasty 
in China. Epidemics of disease in Jakarta, Indonesia, Cairo, Egypt in 1780 may also 
have been dengue and it is thought that DENVs may have become endemic in these 
areas at this time (Gubler 1997). The first recorded outbreak/epidemic of dengue 
occurred in Manila, Philippines between 1953 and 1954. Dengue fever with hemorrhagic 
symptoms emerged in Bangkok, Thailand from 1962 to 1965 (Halstead 1965). In the 
proceeding 20 years, dengue epidemics began appearing in population centers 
throughout Southeast Asia leaving hospitalization and mortality in their wake (WHO 
1986). During World War II, new advances in laboratory techniques led to the 
independent isolation of the first two serotypes of dengue virus, DENV-1 and DENV-2, 
by Japanese (Hotta 1952) and American (Sabin & Schlesinger 1945) researchers. The 
third and fourth serotypes, DENV-3 and DENV-4, were identified during an outbreak in 
the Philippines and Thailand in 1954 (Hammond, Rudnick and Sather 1960). By the 
1980s and 1990s dengue had become a pandemic, spreading in cities from Southeast 
Asia, South Pacific, South Asia, to the Americas (WHO 2009)  
 
2.3 Dengue Epidemiology 
Dengue virus (DENV) belongs to the genus Flavivirus, of which other members 
include Japanese Encephalitis Virus (JEV), Yellow Fever Virus (YFV), and West Nile 
Virus (WNV). The DENV genome is a positive-sense, single strand of RNA 
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approximately 11,000 bases in length (Fields 2006). Infection with any one serotype of 
DENV leads to lifelong protection against the infecting serotype (homologous 
reinfection), however, only brief protection against another serotype (heterologous 
challenge) (Kurane & Ennis 1992). Human transmission of dengue is maintained by the 
domestic Aedes aegypti and peri-domestic Aedes albopictus mosquitoes (Hanley & 
Weaver 2008). 
DENV is widely distributed and circulates in tropical and subtropical regions 
constituting a human health threat of disconcertingly large proportions with 
approximately 100 million infections per year resulting in case fatality rates from 0.2% 
in Paraguay and 0.63% in Malaysia all the way to 2.63% and 8.11% in Indonesia and 
Bhutan respectively (WHO 2014). 2.5 billion people are exposed to the risk of dengue 
infection and the impact and scope of dengue epidemics worldwide has been on a 
precipitous rise, aided by unchecked human population growth in endemic regions and 
the ensuing reclamation and repurposing of land. A recent study (Bhatt et al., 2013) has 
attempted to more accurately assess global rates of dengue infection by combining 
cartographic approaches, longitudinal information and detailed dengue cohort studies 
with risk maps and known dengue occurrences worldwide: Bhatt et al estimate that there 
are 390 million dengue infections per year of which 96 million presented with clinical or 
subclinical severity – more than three times current estimates by the WHO. The 
emergence of dengue as a global pandemic has been linked to mass movement of troops 
during World War II, the growth of international travel, and rapid, unplanned 
urbanization in developing nations where dengue is endemic (Gubler 1998). As of 2011, 
most large urban centers in the tropics spanning the globe from Asia to the Americas are 
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hyperendemic with multiple serotypes of DENV circulating and causing disease (Gubler 
2011). 
 
2.4 Risk Factors for Development of Severe Disease 
Determining the percentage of DENV infections that result in DHF of SD is 
difficult: Kurane & Ennis (1992) have described clinically apparent dengue fever as the 
tip of the iceberg in that less than 10% of symptomatic dengue cases are reported and 
more than 50% of dengue infections are asymptomatic (WHO 2014). Risk factors for 
SD/DHF include ethnicity, viral genotype, and sequence of infecting serotypes (Gubler 
1998). Although the specific mechanism for DHF/SD is currently unknown, there are 
two competing hypotheses for the development of severe disease:  
(i) The antibody (Ab)-dependent enhancement (ADE) theory posits that during 
a second, heterologous DENV infection, heterotypic antibodies from the 
previous infection bind DENV from the second infection but are unable to 
neutralize the virus. The Ab-virus complex then attaches to Fc receptors on 
circulating monocytes and macrophages that then internalize the infectious 
Ab-virus complex. Ab-virus complexes are more readily taken up than 
uncoated virus particles thereby increasing the efficiency with which 
monocytes and macrophages are infected by DENV resulting in higher levels 
of viremia and cytokine release in DHF patients (Halstead 1989; Kliks et al., 
1989; Whitehead et al., 2007).  
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(ii) Certain phenotypes of dengue are more virulent than others – Rico-Hesse et 
al. (1997) compared nucleotide sequences in the E/NS1 gene region of the 
dengue virus genome to demonstrate the association of the introduction of 
two distinct DENV-2 genotypes and the appearance of DHF in the Americas. 
 
2.5 Endemic Dengue Vectors 
 The principal vector for DENV is the anthropophilic, urban mosquito Aedes 
aegypti. Historically implicated by its correlation with the spread of dengue fever 
outbreaks, A. aegypti is now a fully domesticated mosquito and well adapted to its urban 
environment (Smith 1956; Powell 2013). Despite also being the primary vector for the 
Yellow Fever (genus: Flavivirus) and Chikungunya (genus: Alphavirus), its importance 
in Asia is primarily in relation to DENV and not Yellow Fever due to the high morbidity 
and mortality of the former and the absence of the latter in Asia (Barrett & Higgs 2007). 
The peridomestic/forest fringe mosquito Aedes albopictus is also DENV 
competent and Smith (1956) noted its presence in rural areas where human Abs to 
dengue were present, A. aegypti was absent. In a household vector survey in Dhaka, 
Bangladesh during a DF and DHF outbreak Ali et al. (2003) found that households 
reporting a recent dengue illness were more likely to have A. albopictus larvae present 
within the home compared to households not reporting cases implicating A. albopictus 
as the sole vector in some cases. 
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2.6 Enzootic / Sylvatic Dengue Cycle 
Sylvatic Dengue in West Africa 
In contrast with Asian sylvatic dengue, a greater number of studies have 
canvased the ecology of sylvatic DENV transmission in West Africa and, broadly, as of 
2015, the West African cycle is characterized by the presence of DENV-2 as the sole 
strain and an approximately eight-year cycle (Robin et al., 1980; Cornet et al., 1984; 
Saluzzo et al., 1986; Zeller et al., 1990; Cornet 1993, Diallo et al., 2003) The first 
conclusive evidence for an enzootic DENV cycle in West Africa was a the isolation of a 
sylvatic DENV-2 virus from a human near the Senegalese capital Dakar in 1970 and a 
sylvatic DENV-2 from forest-caught pools of Aedes luteocephalus near the town of 
Kédougou in southeastern Senegal (Robin et al., 1980). Serosurveys, in search of a 
forest dwelling host, conducted in Senegal from 1974 and 1985 gathered proof that 
forest primates served as a reservoir (Saluzzo et al., 1986). In one study, neutralization 
assays in Nigeria found DENV neutralizing antibody in monkeys (48%) and galagos 
(25%). Additionally, the same study found that 48% of humans with DENV neutralizing 
antibody were living in “Rainforest Zones” far removed from endemic DENV vectors 
(Fagbami, Monath and Fabiyi 1977). Human endemic DENVs were isolated from forest 
mosquitoes Aedes furcifer, A. taylori, and A. luteocephalus casting suspicion on these 
mosquitoes as putative bridge vectors in forest dengue cycle as these mosquitoes lived in 
forest and forest fringe settings unlike the urban A. aegypti and peridomestic A. 
albopictus species (Diallo et al., 2003). The recovery of human, endemic DENV from 
these mosquitoes implies that they had previously fed on humans. 
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While sylvatic DENV strains are considered to have been the phylogenetic 
progenitors of DENVs transmitted among humans, none have yet been identified as the 
etiologic agents of dengue outbreaks in human populations. With the hypothesis that 
sylvatic DENVs may cause undetected spillover epidemics, a team from the University 
of Texas Medical Branch, examined isolates of DENV recovered from febrile patients at 
University College Hospital in Ibadan, Nigeria from August 1964 to December 1968. 
After amplification with RT-PCR, sequencing, and phylogenetic analysis, 3 of 32 
original Nigerian isolates, all three from 1966, were reported as genetically distinct from 
endemic DENV-2 isolates and fell within the sylvatic DENV-2 clade – evidence 
suggesting that that a sylvatic DENV cycle had spilled over into humans in Ibadan, 
Nigeria in 1966 (Vasilakis, Tesh and Weaver 2008). Virus isolations of sylvatic DENV-
2 continued to lend epidemiological support to the existence of enzootic cycles in West 
Africa, until a sylvatic DENV-2 strain was isolated from Erythrocebus patas monkeys in 
Eastern Senegal (Cornet 1984).  From 1999 to 2000, 6 sylvatic DENV-2 strains were 
isolated from forest mosquitoes (A. furcifer) collected from inside a the town of 
Kedougou in Southeastern Senegal (Diallo et al., 2003). Human endemic DENVs were 
also recovered from forest mosquitoes Aedes furcifer, A. taylori, and A. luteocephalus 
mosquitoes living in forest and forest fringe (Diallo et al., 2003). Given the absence of 
urban A. Aegypti and peridomestic A. Albopictus species in a rainforest environments, it 
is possible that A. furcifer, A. taylori, and A. luteocephalus may serve as potential bridge 
vector between sylvatic DENV transmission cycles in non-human primates and nearby 
human populations. More importantly, while sylvatic DENV has been demonstrated in 
mosquitoes, monkeys, and (recently) humans, studies conducted thus far have not 
isolated/identified sylvatic strains to be active in vector, reservoir, and humans 
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concurrently in space and time, therefore limiting the epidemiologic information that can 
be gleaned about the conditions under which viral spillovers occur in West Africa.  
Sylvatic DENV is capable of causing severe illness in humans: In November 
2009, a 27 year-old man returning to Spain from his home country of Guinea-Bissau, by 
way of Senegal, in West Africa was admitted to hospital with symptoms consistent with 
Grade II Dengue Hemorrhagic Fever.  Serology, PCR, and phylogenetic analysis of the 
causative agent revealed something unexpected: A sylvatic DENV of West African 
lineage designated EEB-7 (Franco et al., 2011). 
 
Sylvatic Dengue in East Asia 
Unlike West Africa, DENV-1, 2, 4 have been detected in Asia, suggesting the 
prospect of hyperendemicity and the near constant circulation of at least one of the three 
serotypes. The first work to lend solid support to the existence of sylvatic DENV was 
that of Gordon Smith on the west Malaysian peninsula during the 1950s.  Serological 
studies conducted on rural Malay communities revealed that 80% of adults possessed 
dengue neutralizing antibodies in areas where A. aegypti mosquitoes, the urban vector 
for endemic DENV, were completely absent (Smith 1958).  Humans were not the only 
species testing positive – Smith (1956) found large numbers of aroboreal mammals with 
neutralizing antibodies such as civets, squirrels and slow lorises (Nycticebus coucang, a 
non-human primate).  He speculated that A. albopictus might maintain dengue 
endemicity in rural settings due to its very large numbers (Smith 1956; Smith 1958).  
Smith hypothesized that the presence of DENV neutralizing antibodies in humans and 
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primates far removed from endemic DENV transmission foci and its vector implied the 
existence of a separate, enzootic DENV cycle in rural and forested areas. The existence 
of the cycle, however, remained unsubstantiated due to a lack of DENV isolation from 
any potential forest vectors. 
By far, the most extensive and intensive DENV ecology surveys ever performed 
in Asia are those of Albert Rudnick performed a decade after Smith during his 
association with Malaysia’s Institute for Medical Research from 1962 to 1980.   Rudnick 
examined forest mammals and primates in habitats ranging from primary and peat 
swamp forests to heavily disturbed plantation areas united by the absence of A. aegypti.  
Serology revealed the presence of DENV neutralizing antibodies in more than 47% of 
Macaca nemestrina, Macaca fascicularis (68%) and Trachypithecus cristatus (Rudnick 
1965) corroborating Smith’s (1956) earlier conclusions of DENV as a zoonosis.  Spurred 
by his initial findings, Rudnick stationed Maccaca and Trachypithecus monkeys as 
sentinels and live bait for mosquitoes in the forest canopy. He succeeded in isolating 
DENV-1 (strain P72-1244), three strains of DENV-2 (P8-1407, P72-1273 and P72-
1274), and three strains of DENV-4 (P75-481, P73-1120 and P75-514) from sentinel 
macaque sera.  Rudnick did not recover any isolates from any of 19 ground-stationed M. 
nemestrina sentinels which may indicate that transmission took place in jungle canopies 
(Rudnick  1986). Concurrent mosquito collections yielded a DENV-4 (P75-215) isolate 
from the sylvatic, canopy dwelling Aedes niveus. Rudnick noted that he increased 
capture numbers of A. niveus considerably when the using human bait instead of dry ice 
or caged macaques (Rudnick 1986) demonstrating that A. niveus opportunistically fed on 
humans. The most recent search for neutralizing antibodies in non-human primates was 
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a serosurvey conducted in Borneo by Wolfe et al. (2001) found DENV-2 specific 
antibodies in orangutans. And yet these primates are unlikely to be a sylvatic dengue 
reservoir due to their extremely low population density of 1 to 2 orangutans per km2 – it 
would be unlikely for an infected mosquito to travel the kilometers between blood meals 
necessary to maintain transmission. 
The role of the common, peri-domestic A. albopictus as a possible vector of 
sylvatic dengue is a subject of contention. Simmons et. al in 1931 demonstrated 
experimentally that A. albopictus is an efficient endemic DENV vector.  This mosquito 
species was later implicated in a dengue fever outbreak in port cities of Japan during 
WWII (Kimura & Hotta 1944; Hotta 1952) and is also a sylvatic DENV vector suspect 
due to its often large numbers near human habitation in forest fringe settings and rural 
land converted to palm oil plantations (Chang et al., 1997). Although A. albopictus was 
already known as a competent endemic dengue vector, Moncayo et al. (2004) compared 
the infection and dissemination rates of endemic and sylvatic DENV-2 in both A. 
aegypti and A. albopictus to determine if endemic dengue had to adapt to these 
peridomestic mosquitoes as a step before cementing the ability to infect humans on a 
large scale.   They discovered that while both Aedes species were highly susceptible to 
endemic dengue infection, they were significantly less susceptible to sylvatic DENV-2.  
The Southeast Asian DENV-2 isolated by Rudnick in 1970 had some of the lowest 
infection rates and the lowest dissemination rate (0%).  Furthermore, Rudnick’s isolation 
of DENV-2 from an A. albopictus mosquito in 1969 was, in retrospect, an endemic strain 
of DENV-2 according to phylogenetic analysis (Wang et al., 2000).  While A. albopictus 
still remains a likely candidate for a sylvatic dengue bridge vector, these studies 
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collectively suggest that other Aedes mosquitoes are also competent and merit further 
study. It is also possible that normally primatophillic mosquitoes shift their feeding 
preference from forest primates to humans.  A change in mosquito feeding behavior has 
been implicated in the spread of West Nile Virus (also a flavivirus like DENV) in the 
U.S.A. (Gómez et al., 2008). Given Rudnick’s observation that A. niveus mosquitoes 
displayed a preference for biting humans when given the choice between carbon dioxide 
bait, macaques and humans, a change in forest-dwelling Aedes mosquito feeding 
behavior may play a role in sylvatic DENV spillover event. Hypothetically, an Aedes 
mosquito normally involved in an enzootic DENV transmission cycle opportunistically 
shifts its feeding preference to humans allowing the transfer of sylvatic DENV into the 
human host/population. As more time passes, the sylvatic DENV competent mosquito 
may shift its preference to humans entirely resulting in the emergence of sylvatic DENV 
in a human population. 
In January of 2008, a 20-year-old male student at Universiti Malaysia Sarawak 
was admitted to hospital after developing DHF Grade II two days after he had returned 
home from a four-week stay in Peninsular Malaysia (where he traveled along the 
western slopes of the Main Range).  Blood drawn on day four of his fever revealed the 
causative agent to be a DENV-2.  A DENV-2 isolate (DKD811) was cultured from 
blood samples and sequenced.  Subsequent phylogenetic analysis yielded unexpected 
results: DKD811 was a sylvatic DENV-2 strain (Cardosa et al., 2009).  Not only was 
this the first recorded case of DHF in a human of sylvatic DENV origin, but it was also 
the first definitive case of a human acquiring sylvatic DENV in Malaysia. Further 
phylogenetic investigation and molecular clock analysis closely matched DKD811 with 
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a sylvatic DENV-2 strain (P8-1407/1970) isolated from a monkey in Tanjong Rabok, 
Selangor, Malaysia by Rudnick in 1970, making the new isolate the first evidence of 
sylvatic dengue in Asia since the 1970s (Cardosa et al., 2009).  The sylvatic strain P8-
1407 is closely matched with DKD811 and was isolated from this same general location 
(Rudnick 1986). At the conclusion of his studies in peninsular Malaysia, Rudnick (1986) 
had successfully isolated sylvatic strains of DENV-1, DENV-2, and DENV-4 from 
Aedes species mosquitoes or non-human primates and although a sylvatic DENV-3 was 
never isolated, its existence was inferred from Rudnick’s detection of DENV-3 
neutralizing Abs in non-human primates. 
Recently, Teoh et al. (2010) retrospectively analyzed the envelope gene 
sequqnce of 442 endemic DENV-1 isolates from a 2004 - 2007 dengue fever outbreak in 
Malaysia. One isolate (D1.Malaysia.36046/05) shared 97% nucleotide sequence and 
99% amino acid sequence similarity with isolate P72-1244 – a DENV-1 isolated by 
Rudnick (1986). Hospital records indicated that the virus was isolated from a patient that 
displaying symptoms consistent with dengue at University of Malaya Medical Centre 
(Teoh 2010). Although D1.Malaysia.36046/05 was originally isolated from a sentinel 
monkey (M. fascicularis) in a rural area of peninsular Malaysia in 1972, it’s status as a 
sylvatic strain has come in to question because it has recently been determined to be 
phylogenetically more similar to endemic DENV-1 (Rudnick 1986; Vasilakis and 
Weaver 2008). The detection of the isolate is important in either outcome: If sylvatic, it 
would be the latest example of a dengue zoonosis into a human host. If originally 
endemic, it demonstrates that endemic DENVs can spillback into monkeys.  
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Sylvatic Dengue Elsewhere 
 Evidence for the presence of a sylvatic DENV cycle in the Americas comes from 
serovconversion (by PRNT) to DENV-2 of Native Americans living in the remote area 
of Ayoreo, Bolivia (Roberts et al., 1984). RNA representing four DENV serotypes was 
detected in marsupials, rodents, bats and deer from liver and/or sera – the first evidence 
of dengue virus infection of neotropical forest mammals (de Thoisy et al., 2009). 
According to de Thoisy et al.  (2009), “Sequence analyses of a portion of the capsid and 
premembrane junction revealed that mammal strains of DENV-1, DENV-2, DENV-3, 
and DENV-4 had only 92.6%, 89%, 95%, and 95.8% identity, respectively, with strains 
circulating in the human population during the same periods.” Although the short RNA 
sequence evidence suggests that these DENV detections may be sylvatic, only complete 
virus isolation and complete genetic characterization can definitively distinguish 
between an endemic and sylvatic DENV. Another possibility is that these detections in 
French Guiana may be endemic DENVs that have spilled back into forest mammals.  
 
2.7 Origins of Dengue 
 Zanotto et al. (1996) reconstructed the phylogeny of 123 complete DENV 
envelope genes in a maximum likelihood tree for each of the four serotypes to determine 
how the four endemic serotypes were related to each other. According to their analyses, 
DENV-4 was first to diverge followed by DENV-2 then DENV-1 and DENV-3. The 
origin of dengue still remained uncertain. Had it been with humanity from the dawn of 
our species or had it emerged relatively recently? Gubler (1997) posited that endemic 
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DENV originated from a sylvatic form of the virus that circulated in non-human 
primates and forest Aedes mosquitoes as vectors. Wang et al. (2000) tested Rudnick’s 
hypothesis by sequencing the complete envelope (E) protein gene of DENV-1, -2, and -4 
strains collected by Rudnick (1986) during his forest surveys in Malaya during the 1970s 
as well as sylvatic DENV-2 strains from West Africa. Notably, Wang et al. (2000)’s 
phylogenetic trees placed the African and East Asian sylvatic isolates at positions that 
were basal to their respective dengue serotype groups:  
 
“[It is] estimated that the sylvatic DENV-2 genotypes diverged from the 
endemic/epidemic forms on the order of 1,000 ± 500 years ago (estimate ± standard 
deviation). The African and Malaysian sylvatic lineages of DENV-2 diverged on the 
order of 800 ± 400 years ago. Sylvatic and endemic/epidemic DENV-1 and -4 probably 
diverged on the order of 200 ± 100 and 600 ± 300 years ago respectively.”   
 
These estimates for DENV emergence also coincide approximately with the rise 
of human population centers large enough to support epidemic transmission of dengue 
(Gubler 1997, Wang et al., 2000). The asynchronous divergence estimates yielded by 
phylogenetic analyses suggest the endemic/epidemic lineages of DENV-1, -2, and -4 
evolved/emerged independently of one another from sylvatic viruses circulating in the 
Asian-Oceania region (Wang et al. 2000) – in other words, these emergence events 
happened separately and repeatedly for each dengue serotype giving rise to the four 
known endemic serotypes in circulation today. Gubler (1997) hypothesized that each of 
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these emergence events would have involved a sylvatic DENV switching from forest 
canopy-dwelling Aedes mosquito vectors to A. albopictus and later A. aegypti. Since this 
would have presumably happened in rural locations lacking A. aegypti,  A. albopictus or 
other Aedes mosquitoes may have been the original human vectors (Smith 1956).  
 Twiddy, Holmes and Rambaut (2003) conducted a study similar to Wang et al. 
(2000)’s phylogenetic study of sylvatic and endemic DENV envelope (E) gene 
sequences, but incorporated additional information about times of virus sampling. 
Although in general agreement with Wang et al. (2000) that dengue virus appeared circa 
1100 years ago, Twiddy et al. (2003) estimate that the zoonotic divergence events (the 
transfer of virus from monkeys to humans) of endemic from sylvatic dengue are nearly 
three times more recent:  
 
“The dates for the data sets that combine human and sylvatic strains are approximately 
320 years ago for DENV-2, 200 years ago for DENV-4, and 125 years ago for DENV-
1 . . . For all four serotypes, these estimates place the beginning of the epidemic 
transmission of dengue in humans near to the end of the nineteenth and the beginning of 
the twentieth century.” 
 
Hanley and Weaver (2010) theorize that if Twiddy et al.’s estimates are correct, then 
DENV strains that caused epidemics before the 18th century may have gone extinct and 
been replaced by more recent sylvatic strains.  
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The question as to the origin of the four extant serotypes of DENV is still open 
today. Presumably, it is unlikely that the serotypes would diverge from the same/shared 
geographic location due to robust and enduring host immunity to homologous 
reinfection – any virus wasn’t significantly different antigenically would be 
competitively excluded. Rather, it is more likely that the four serotypes of DENV are 
allopatric and evolved from sylvatic strains that were geographically isolated relative to 
one another. Once human population centers had become large enough, these allopatric 
sylvatic serotypes then emerged in separate events evolving into the four known 
endemic serotypes (Vasilakis et al., 2007). Once the four serotypes had significantly 
diverged so as to offer only limited cross-reactive immunity upon heterologous 
challenge, the rise of international travel/commerce and concomitant spread of Aedes 
aegypti facilitated the spread of multiple serotypes resulting in areas of hyperendemicity 
in the tropics (eg. Malaysia) (Gubler 1997, Vasilakis et al., 2007). If all four serotypes of 
DENV emerged recently and independently as Twiddy et al. (2003) estimate, then the 
probability of a sylvatic DENV strain spilling over into a human population and 
evolving to a primarily human host/vector cycle is larger than if only one such even had 
taken place in the past. 
 
2.8 Possibility of Spillover or Sylvatic Dengue Emergence 
While studying the Yellow Fever Virus (genus Flavivirus) in the Central African 
Republic, Germain (1976) noted the high density of peridomestic and forest Aedes 
vectors in the boundary between the forest and savanna ecotopes where many isolates of 
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Yellow Fever had previously been recovered from humans and mosquitoes and where 
humans and forest animals were both present.  Germain (1976) coined the term “zones 
of emergence” to refer to such places where sylvatic cycles of disease could spillover 
and cause human pathology. As global population increases and forest is cleared for 
development these zones of emergence are growing larger and more common.  
This is especially true of developing countries in the tropics. Malaysia is a prime 
candidate that fits many risk criteria for emergence: (i) it is developing rapidly with 
resultant deforestation and changing land use creating “zones of emergence” (ii) sylvatic 
DENV-1, DENV-2, and DENV-4 have been isolated from non-human primates and 
forest/peridomestic Aedes vectors (Rudnick 1986)  (iii) a sylvatic dengue virus has 
caused severe disease (DHF) in humans (Cardosa et al., 2009) (iv) and endemic dengue 
viruses may be spilling back into forest and forest fringe monkeys (Teoh 2010).  
 Some are skeptical if sylvatic dengue viruses pose a threat to public health. In a 
reviewing the role of monkeys in the biology of dengue, Rodhain (1991) states: 
 
“The constant reduction in size of natural forests tends to make the original 
simian epidemiologic cycle somewhat of a relic which, at present, has practically no 
importance as a reservoir. It would be necessary to take it into consideration only if, 
before its disappearance the inter-human died out, for example as the result of 
vaccination . . .” 
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While it may be true that enzootic DENV hosts like M. fascicularis are on the 
decline, they also show remarkable ability to adapt and thrive in urban peri-urban 
environments and it remains to be seen if they will eventually adapt entirely to an urban 
environment as in the case of 131 M. fascicularis recently discovered living in the 
middle of Bangkok, Thailand (Eudey 2008; Chatpiyaphat and Boonratana 2013). While 
habitat destruction continues, sizeable forest reserves in the form of national parks (eg. 
Taman Negara in Malaysia) may be large enough to maintain sylvatic transmission 
cycles. Whatever the truth of the matter may be, one fact remains: No data, serological 
or otherwise, has been collected about the whereabouts of sylvatic transmission cycles in 
non-human primates in Malaysia for almost four decades (Rudnick 1986) and any 
hypotheses regarding the presence, decline, or absence of these sylvatic DENV cycles 
can be supported or refuted without new/current data. 
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CHAPTER 3 – MATERIALS AND METHODS 
 
 
3.1 Primate Serum Samples 
Serum samples were received from the Department of Wildlife and National 
Parks (Perhilitan), Peninsular Malaysia headquarters in Cheras, Selangor in aliquots 
ranging from 50 – 60 µl in 1.5 ml Eppendorf microfuge tubes.  Officers of the ex-situ 
team, DWNP, obtained these blood samples during outings including, but not limited to 
DWNP surveys and nuisance animal relocations. These samples were collected by 
DWNP staff during officially sanctioned, routine outings for the department’s own use 
during 2009. No sample collection was specifically performed for this study – As such, 
no ethics release was required. Samples were transferred from freezer storage at -20 ºC 
at Perhilitan into thick-walled polystyrene coolers packed with dry ice −78.5 °C then 
immediately transported by car to the Venture Technologies Sdn Bhd laboratory at the 
Institute for Research in Molecular Medicnine (INFORMM), Universiti Sains Malaysia, 
Pulau Pinang where they were stored at −80 °C. Sample processing flow is summarized 
in Figure 3.1. 
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Figure 3.1 Flowchart of research acitivities. 
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